PD
Therapeutic Areas
Actinium Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Iomab-B (apamistamab-I-131) | Relapsed/Refractory AML prior to Bone Marrow Transplant | Phase 3 |
| Actimab-A (lintuzumab-Ac-225) | Relapsed/Refractory AML | Phase 2/3 |
| ATNM-400 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Preclinical |
| Iomab-ACT | Conditioning for Cell & Gene Therapies | Research |
Leadership Team at Actinium Pharmaceuticals
SS
Sandesh Seth
Chief Executive Officer and Chairman of the Board
AK
Adeela Kamal
Executive Vice President, Head of Research and Development
JG
Julie Gibson
Vice President, Portfolio and Clinical Operations
RC
Ryan Chu
Vice President, Finance and Investor Relations
CD
C. David Nicholson
Lead Independent Director
AS
Ajit Shetty
Director